# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ironwood 2024 Financial Guidance. Ironwood has revised its FY 2024 financial guidance due to a LINZESS gross-to-net change in...
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly losses of $(0.02) per share which missed the analyst consensus estima...
First prospective trial of a glucagon-like peptide (GLP-2) analog in SR GI aGVHD. Results up to Day 91 show that apraglutide...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Wells Fargo analyst Mohit Bansal maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Overweight and lowers the price tar...
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed four...